

Since this is a very extensive table, the format and content has not been edited by ActaDV.

Table SIII. Summary of metastatic cutaneous squamous cell carcinoma (mcSCC) characteristics

mcSCC characteristics	Total (Male+Female)	Male	Female	P value
Number of patients with mcSCC	82 (100.0)	55 (67.1)	27 (32.9)	
Number of mcSCCs per patient				
One	79 (96.3)	53 (96.4)	26 (96.3)	
Two	3 (3.7)	2 (3.6)	1 (3.7)	
Primary mcSCCs in total	85 (100.0)	57 (67.1)	28 (32.9)	
Ordinal number of primary mcSCC, ref n	85	57	28	.89
First, n (%)	72 (84.7)	49 (86.0)	23 (82.1)	
Second, n (%)	7 (8.2)	4 (7.0)	3 (10.7)	
Third or later, n (%)	6 (7.1)	4 (7.0)	2 (7.1)	
Range, n	1-24	1-24	1-5	
AK and/or cSCCIS diagnosed prior to or on day of primary mcSCC diagnosis, ref n	85	57	28	.91
Yes, n (%)	25 (29.4)	17 (29.8)	8 (28.6)	
No, n (%)	60 (70.6)	40 (70.2)	20 (71.4)	
AK, cSCCIS, cSCC, BCC and/or MTC diagnosed prior to or on day of primary mcSCC diagnosis, ref n	85	57	28	.56
Yes, n (%)	31 (36.5)	22 (38.6)	9 (32.1)	
No, n (%)	54 (63.5)	35 (61.4)	19 (67.9)	

					M:F ratio
Primary tumor location, ref n	85	57	28	.14	
Head and neck, n (%)	70 (82.4)	48 (84.2)	22 (78.6)		1.1
Scalp, n (% of head and neck)	3 (4.3)	3 (6.3)	0 (0.0)		NA
Forehead, n (% of head and neck)	4 (5.7)	2 (4.2)	2 (9.1)		0.5
Temple, n (% of head and neck)	10 (14.3)	7 (14.6)	3 (13.6)		1.1
Orbita, n (% of head and neck)	4 (5.7)	2 (4.2)	2 (9.1)		0.5
Nose, n (% of head and neck)	3 (4.3)	2 (4.2)	1 (4.5)		1.0
Upper lip, n (% of head and neck)	2 (2.9)	2 (4.2)	0 (0.0)		NA
Lower lip, n (% of head and neck)	10 (14.3)	5 (10.4)	5 (22.7)		0.5
Cheek ^a , n (% of head and neck)	4 (5.7)	2 (4.2)	2 (9.1)		0.5
Preauricular, n (% of head and neck)	12 (17.1)	6 (12.5)	6 (27.3)		0.5
Auricle, n (% of head and neck)	12 (17.1)	12 (25.0)	0 (0.0)		NA
Retroauricular, n (% of head and neck)	3 (4.3)	3 (6.3)	0 (0.0)		NA
Neck, n (% of head and neck)	3 (4.3)	2 (4.2)	1 (4.5)		1.0
Trunk, n (%)	2 (2.4)	1 (1.8)	1 (3.6)		0.5
Shoulder, n (% of trunk)	1 (50.0)	0 (0.0)	1 (100.0)		NA
Thorax, n (% of trunk)	0 (0.0)	0 (0.0)	0 (0.0)		NA
Abdomen, n (% of trunk)	0 (0.0)	0 (0.0)	0 (0.0)		NA
Back, n (% of trunk)	0 (0.0)	0 (0.0)	0 (0.0)		NA

Pelvic, n (% of trunk)	1 (50.0)	1 (100.0)	0 (0.0)		NA
Upper limb, n (%)	6 (7.1)	4 (7.0)	2 (7.1)		1.0
Brachium, n (% of upper limb)	0 (0.0)	0 (0.0)	0 (0.0)		NA
Antebrachium, n (% of upper limb)	1 (16.7)	1 (25.0)	0 (0.0)		NA
Wrist, n (% of upper limb)	1 (16.7)	0 (0.0)	1 (50.0)		NA
Hand, n (% of upper limb)	4 (66.7)	3 (75.0)	1 (50.0)		1.5
Lower limb, n (%)	7 (8.2)	4 (7.0)	3 (10.7)		0.7
Thigh, n (% of lower limb)	1 (14.3)	0 (0.0)	1 (33.3)		NA
Knee, n (% of lower limb)	1 (14.3)	1 (25.0)	0 (0.0)		NA
Shin, n (% of lower limb)	5 (71.4)	3 (75.0)	2 (66.7)		0.7
Foot, n (% of lower limb)	0 (0.0)	0 (0.0)	0 (0.0)		NA
Unknown, n (%)	0 (0.0)	0 (0.0)	0 (0.0)		NA
mcSCC characteristics	Total (Male+Female)	Male	Female	P value	
Primary mcSCC locally recurred prior to metastasis detection, ref n	85	57	28		
Yes, n (%)	28 (32.9)	17 (29.8)	11 (39.3)	.38	
No, n (%)	57 (67.1)	40 (70.2)	17 (60.7)	.38	
Number of local recurrences				.53	
0, n (%)	57 (67.1)	40 (70.2)	17 (60.7)		
1, n (%)	21 (24.7)	13 (22.8)	8 (28.6)		

2, n (%)	3 (3.5)	1 (1.8)	2 (7.1)	
3 or more, n (%)	4 (4.7)	3 (5.3)	1 (3.6)	
Primary mcSCC locally recurred overall, ref n	85	57	28	
Yes, n (%)	35 (41.2)	23 (40.4)	12 (42.9)	.83
No, n (%)	50 (58.8)	34 (59.6)	16 (57.1)	.83
Number of local recurrences				.78
0, n (%)	50 (58.8)	34 (59.6)	16 (57.1)	
1, n (%)	18 (21.2)	13 (22.8)	5 (17.9)	
2, n (%)	6 (7.1)	3 (5.3)	3 (10.7)	
3 or more, n (%)	11 (12.9)	7 (12.3)	4 (14.3)	
Metastases:				
Initial metastasis detection, ref n	85	57	28	
Clinical suspicion, n (%)	62 (72.9)	43 (75.4)	19 (67.9)	
Prior imaging performed, n (%)	22 (35.5)	17 (39.5)	5 (26.3)	
of clinically detected)				
Prior sentinel ^b performed, n (%)	2 (3.2)	0 (0.0)	2 (10.5)	
of clinically detected)				
No prior staging, n (% of clinically detected)	38 (61.3)	26 (60.5)	12 (63.2)	
Subclinical imaging, n (%)	19 (22.4)	12 (21.1)	7 (25.0)	

Prior imaging performed, n (% of subclinical imaging)	2 (10.5)	1 (8.3)	1 (14.3)	
Prior sentinel ^b performed, n (% of subclinical imaging)	0 (0.0)	0 (0.0)	0 (0.0)	
First staging exam, n (% of subclinical imaging)	17 (89.5)	11 (91.7)	6 (85.7)	
Sentinel node biopsy, n (%)	4 (4.7)	2 (3.5)	2 (7.1)	
Prior imaging performed, n (% of sentinel node biopsy)	2 (50.0)	1 (50.0)	1 (50.0)	
First staging exam, n (% of Sentinel node biopsy)	2 (50.0)	1 (50.0)	1 (50.0)	
Time between initial diagnosis of primary mcSCC and its first metastasis				
Metastasis diagnosed prior to or on day of initial primary mcSCC diagnosis	7 (8.2)	7 (12.3)	0 (0.0)	
Median (IQR), d	198 (62-527)	160 (39-625)	235 (72-481)	.44
Mean, d	429	448	390	
Range, d	0-7180	0-7180	13-2217	
Within first 6 months, n (%)	42 (49.4)	29 (50.9)	12 (42.9)	
Within first year, n (%)	55 (64.7)	37 (64.9)	18 (64.3)	
Within first 2 years, n (%)	72 (84.7)	48 (84.2)	24 (85.7)	
First detected metastasis, ref n	85	57	28	

Lymph node, n (%)	82 (96.5)	69 (98.6)	26 (92.9)		
Cutaneous, n (%)	3 (3.5)	1 (1.4)	2 (7.1)		
mcSCC characteristics					
Location of 1 st detected nodal metastasis in relation to primary tumor location (ref n)	Total (n=85)	Head and neck (n=70)	Upper limb (n=6)	Lower limb (n=7)	Trunk (n=2)
Ipsilateral neck, n (%)	23 (27.1)	23 (35.9)	0 (0.0)	0 (0.0)	0 (0.0)
Ipsilateral parotid gland, n (%)	31 (36.5)	31 (44.3)	0 (0.0)	0 (0.0)	0 (0.0)
Ipsilateral submandibular gland, n (%)	3 (3.5)	3 (4.3)	0 (0.0)	0 (0.0)	0 (0.0)
Ipsilateral submandibular or submental, n (%)	10 (11.8)	10 (14.3)	0 (0.0)	0 (0.0)	0 (0.0)
Ipsilateral armpit, n (%)	7 (8.2)	0 (0.0)	6 (100.0)	0 (0.0)	1 (50.0)
Ipsilateral groin, n (%)	7 (8.2)	0 (0.0)	0 (0.0)	6 (85.7)	1 (50.0)
Contralateral neck, n (%)	1 (1.2)	1 (1.4)	0 (0.0)	0 (0.0)	0 (0.0)
	Total (Male+Female) 85	Male 57	Female 28	P value	
Cutaneous metastasis, n (%)	12 (14.1)	9 (15.8)	3 (10.7)	.74	
Distant metastasis (excluding distant nodal Metastases), n (%)	13 (15.3)	10 (17.5)	3 (10.7)	.53	
Pulmonary metastasis, n (%)	7 (8.2)	4 (7.0)	3 (10.7)	.68	
Pleural metastasis, n (%)	1 (1.2)	1 (1.8)	0 (0.0)	>.99	

Bone metastasis, n (%)	4 (4.7)	3 (5.3)	1 (3.6)	>.99
Liver metastasis, n (%)	3 (3.5)	3 (5.3)	0 (0.0)	.55
Splenic metastasis, n (%)	1 (1.2)	1 (1.8)	0 (0.0)	>.99
Abdominal metastasis (unspec.), n (%)	1 (1.2)	0 (0.0)	1 (3.6)	.33
Pericardial metastasis, n (%)	1 (1.2)	1 (1.8)	0 (0.0)	>.99
Adrenal gland metastasis, n (%)	2 (2.4)	2 (3.5)	0 (0.0)	>.99
Renal metastasis, n (%)	1 (1.2)	1 (1.8)	0 (0.0)	>.99
Nodal metastasis, ref n	85	57	28	>.99
Yes, n (%)	83 (97.6)	56 (98.2)	27 (96.4)	
No, n (%)	2 (2.4)	1 (1.8)	1 (3.6)	
Location of nodal metastases, ref n	83	56	27	.65
Parotid gland, n (%)	34 (41.0)	22 (39.4)	12 (44.4)	
Submandibular gland, n (%)	4 (4.8)	2 (3.6)	2 (7.4)	
Submandibular/submental, n (%)	13 (15.7)	7 (12.5)	6 (22.2)	
Neck, n (%)	45 (54.2)	30 (53.6)	15 (55.6)	
Supraclavicular, n (%)	4 (4.8)	2 (3.6)	2 (7.4)	
Armpit, n (%)	9 (10.8)	6 (10.7)	3 (11.1)	
Mediastinal, n (%)	8 (9.6)	6 (10.7)	2 (7.4)	
Para-aortal, n (%)	1 (1.2)	1 (1.8)	0 (0.0)	
Iliac, n (%)	2 (2.4)	2 (3.6)	0 (0.0)	
Groin, n (%)	8 (9.6)	5 (8.9)	3 (11.1)	.71
Number of nodal metastases, ref n	83	56	27	.63

One, n (%)	31 (37.3)	21 (37.5)	10 (37.0)	
Two, n (%)	10 (12.0)	8 (14.3)	2 (7.4)	
Three or more, n (%)	42 (50.6)	27 (48.2)	15 (55.6)	
Diameter of largest nodal metastasis, ref n	83	56	27	.95
0-30mm, n (%)	42 (50.6)	29 (51.8)	13 (48.1)	
30,1-60mm, n (%)	24 (28.9)	16 (28.6)	8 (29.6)	
>60mm, n (%)	17 (20.5)	11 (19.6)	6 (22.2)	
mcSCC characteristics	Total (Male+Female)	Male	Female	P value
Extranodal extension (ENE), ref n	83	56	27	
Yes, n (%)	48 (57.8)	31 (55.4)	17 (63.0)	.51
No, n (%)	35 (42.2)	25 (44.6)	10 (37.0)	.51
Contralateral to primary tumor nodal metastasis, ref n	83	56	27	
Yes, n (%)	10 (12.0)	7 (12.5)	3 (11.1)	>.99
No, n (%)	73 (88.0)	49 (87.5)	24 (88.9)	>.99
Locally advanced, ref n	85	57	28	>.99
Not, n (%)	45 (52.9)	30 (52.6)	15 (53.6)	
Primary tumor locally advanced, n (%)	15 (17.6)	10 (17.5)	5 (17.9)	

Metastasis locally advanced, n (%)	23 (27.1)	16 (28.1)	7 (25.0)	
Primary tumor and metastasis locally advanced, n (%)	2 (2.4)	1 (1.8)	1 (3.6)	
Curation data, ref n	85	57	28	
Metastatic disease cured and in remission until the end of follow-up				
Yes, n (%)	31 (36.5)	22 (38.6)	9 (32.1)	.52
No, n (%)	50 (58.8)	31 (56.1)	18 (64.3)	.52
Unknown, n (%)	4 (4.7)	3 (5.3)	1 (3.6)	
Mortality, ref n	82	55	27	
Alive at the end of follow-up, n (%)	22 (26.8)	15 (27.3)	7 (25.9)	.90
Deaths in total, n (%)	60 (73.2)	40 (72.7)	20 (74.1)	.90
Disease-specific death, n (% of dead)	43 (71.7)	26 (65.0)	17 (85.0)	.11
Among age bands				
<70, n (% of dead)	6/8 (75.0)	4/6 (66.7)	2/2 (100.0)	
70-79, n (% of dead)	10/16 (62.5)	9/14 (64.3)	1/2 (50.0)	.02
80-89, n (% of dead)	20/27 (74.1)	12/18 (66.7)	8/9 (88.9)	
≥90, n (% of dead)	7/9 (77.8)	1/2 (50.0)	6/7 (85.7)	.02

^aExcluding preauricular region. ^bSentinel node biopsy.

AK: actinic keratosis; BCC: basal cell carcinoma; cSCCIS: cSCC *in situ*; IQR: interquartile range; MTC: metatypical carcinoma; NA: not applicable.